| Ticker | ALXN |
|---|---|
| ISIN | US0153511094 |
| Sector | Atención sanitaria |
| Industria | Biotechnology |
| Mercado | NASDAQ |
| Beta | 1,26 |
| Sitio web | http://www.alexion.com |
| CEO | Ludwig Hantson |
| Fecha de IPO | 01/02/1996 |
| País | US |
| Dirección | 121 Seaport Blvd, Boston, MA, 02210 |
| Volumen | 3 |
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enz...
El precio actual de Alexion Pharmaceuticals (ALXN) es de 182,50 , con una variación del 0,00%.
Alexion Pharmaceuticals opera en el sector Healthcare, industria Biotechnology.
Compara brokers con acceso a las principales bolsas internacionales, con bajas comisiones, custodia y herramientas de análisis para invertir en acciones.
Compara brokers para acciones